Roche takes $2 billion punt on UCB Alzheimer's candidate

29 July 2020

Shares of Belgium’s largest drugmaker UCB (Euronext Brussels: UCB) were barely moved in early trading, despite the announcement of a potentially massive licensing deal for its Alzheimer’s candidate.

UCB has entered into a world-wide, exclusive license agreement with Swiss pharma giant Roche (ROG: SIX) and its biotech arm Genentech, for the global development and commercialization of UCB0107 in Alzheimer’s disease (AD), a therapy area that has failed to bring any cures to the market so far.

The transaction remains subject to obtaining antitrust clearance and other customary closing conditions. This license agreement does not impact UCB’s 2020 financial outlook, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK